It is undeniable that the increase in IL-1β production is associated with the development of periodontal disease [69] and that the use of inhibitors of this cytokine contributes to the reduction of periodontal bone loss in primates [70], so it is suggested that the monitoring of IL1β levels is a useful approach for determining therapeutic outcomes and a potential target treatments for PD [69, 71]. This evidence concerns the gene IL1B and periodontal disorder.